Introduction: The prevalence of smoking during pregnancy for Alaska Native (AN) women is more than triple that of non-Native Alaska women. In this qualitative study, we solicited input from AN women and others to determine how best to present findings from an earlier study demonstrating a strong correlation between biomarkers for maternal smoking (cotinine) and neonatal exposure to a tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) to motivate cessation. Methods: We developed a brochure incorporating generalized biomarker information. Using indepth individual interviews with pregnant and postpartum AN women and partners/family members, we explored applicability and acceptability of the information. Postpartum women, who had participated in the earlier correlation study, additionally received their individual biomarker results. We assessed whether being presented general or individual biomarker information would motivate cessation using content analysis. Results: We conducted 39 interviews: 16 pregnant women, 12 postpartum women, and 11 partners/ family members. Overall, participants agreed the biomarker information was new, but understandable as presented. Postpartum women shared that learning their personal results inspired them to want to quit or cut back smoking while pregnant women indicated the generalized correlation information was less helpful in motivating cessation. Conclusion: Generalized information about fetal exposure to carcinogens may be more effective in motivating pregnant women to quit smoking when combined with individual cotinine testing. Implications: Using feedback from this study, we refined and are currently evaluating an intervention incorporating generalized correlation information from Phase I and cotinine testing to determine its effectiveness in motivating smoking cessation among pregnant AN women.
Introduction
More than 1000 US infant deaths annually are attributable to smoking during pregnancy. 1 Data from the Alaska Pregnancy Risk Assessment Monitoring System indicate the prevalence of cigarette smoking during the last trimester of pregnancy was 29.8% among Alaska Native (AN) women compared to 8.6% among non-Native Alaskan women and this prevalence has not changed substantially in the past 10 years. 2 Additionally, AN women have lower spontaneous tobacco use quit rates during pregnancy and higher relapse rates postpartum than non-Native Alaskan women. 3 Moreover, adult offspring of mothers who smoked during pregnancy are twice as likely to use tobacco later in life. 4, 5 Overall, smoking prevalence among Alaskan adults (22%) is higher than that of the US general population (18%). This disparity is even greater among AN adults, whose smoking prevalence (42%) is more than double the US prevalence. 6 Cancer has remained the leading cause of death among AN people since the mid-1990s, with lung cancer a leading cause of cancer incidence and mortality. 7 More than 90% of lung cancers are attributed to smoking. 8 Links established between smoking and stomach, liver, and colorectal cancers 9 continue to contribute to greater incidence rates of these cancers among AN people than among US whites. 7 The deleterious effects of smoking observed in this population throughout the lifespan serve to decrease life expectancy, expand health disparities, and underscore the immediate need to dramatically reduce smoking prevalence among AN people. While tobacco cessation clinical programs exist throughout the Alaska Tribal Health System, these have not been integrated into routine prenatal care and do not specifically address the harmful health effects smoking during pregnancy has on mothers and their babies. Only one prior pilot study intervention conducted with AN pregnant women suggested participants desired "objective" feedback on how tobacco could harm their baby. 10 Smoking cessation interventions for pregnant women have not been effective. Most biomarker feedback interventions for smoking cessation operate under the assumption that health behavior is influenced by one's perceived risk or harm caused by unhealthy habits. 11, 12, 13 Fact-based emotional appeals used in a national social marketing campaign have had significant impact on smokers quitting. 14 When presented with risk information such as that used in biomarker feedback interventions, research has shown that successful adaptive and preventive behavior change relies on concepts of self-efficacy (confidence in one's ability to change) and response efficacy (belief that the behavior change will reduce health risks). 15, 16 "The Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women" (MAW) study is a three-phase study designed to incorporate this feedback in an AN-specific prenatal intervention. We previously reported results of the first phase of the study (Phase I) demonstrating a strong correlation between maternal smoking and neonatal exposure to tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). 17 Here we report results of the second phase in which we assessed the application and acceptability of the biomarker information derived from Phase I as part of an intervention to motivate smoking cessation among AN women during pregnancy. Specifically, we explored how best to present the biomarker information and whether providing women feedback on their infants' likely exposure to NNAL would enhance motivation to quit smoking.
Materials and Methods
This qualitative study extended the long-standing research partnerships between Alaska Native Tribal Health Consortium (ANTHC) and Southcentral Foundation (SCF) in Anchorage, Alaska and Mayo Clinic in Rochester, Minnesota. The Alaska Area and Mayo Clinic Institutional Review Boards and the ANTHC and SCF Boards of Directors approved the study. The study was registered with clinicaltrials.gov (NCT02018640). Phase II study enrollment and data collection occurred between December 2013 and November 2014; data were analyzed in 2015.
Health Messaging Framework
Our biomarker feedback intervention was intended to provide facts about the association of maternal cotinine and infant NNAL while simultaneously raising expectations of a healthier baby resulting from cessation (ie, positive or gain-framed messages 18 ) and enhancing social influences that would reinforce healthy behaviors. 19 
Community Advisory Board
We formed a community advisory board (CAB) consisting of interested AN adult community members to provide input on the presentation of the data and the interview questions. Outreach efforts for CAB participation included flyers, booths at local events, and snowball recruitment methods employed by CAB members themselves. CAB members received an overview of the study, education on nicotine and tobaccospecific carcinogen exposure, and a $20 gift card for each meeting they attended. Although CAB composition varied over the course of the study, a core group of four AN community members provided guidance on study design and recruitment methods and materials; intervention presentation graphics, layout, and messaging; and interview content and questionnaire wording from a community-based, cultural perspective during monthly meetings with study investigators.
Study Design
We conducted in-depth interviews exploring perspectives of pregnant or recently delivered AN women who were presented the biomarker correlation findings from Phase I. We chose individual interviews over focus groups to reduce scheduling barriers. We designed interviews to obtain demographic information, explore participants' thoughts and feelings about the information and its presentation, and solicit recommendations for tailoring a cessation program specifically to pregnant AN women. We analyzed responses from women who received generalized biomarker correlation information versus women who also received their cotinine levels. Thus, we recruited two groups of women to interview as Index participants: (1) women who had participated in Phase I, had since delivered, and had provided a urine sample for cotinine analysis at delivery (Index Postpartum), and (2) women who were pregnant, but did not participate in Phase I (Index Prenatal). Index participants were assessed for their readiness to quit smoking based on the validated Contemplation Ladder. 20 Upon our CAB's recommendation, we extended study participation to family members or close friends of Index Participants, referred to as Secondary Participants, to explore potential social influences and support roles as part of developing the intervention.
Study Setting, Sampling Strategy, and Eligibility Criteria
Study enrollment and interviews were conducted in-person primarily on the Alaska Native Health Campus (ANHC) in Anchorage, Alaska.
We used stratified purposeful sampling to enroll Index participants (Postpartum and Prenatal). Index participants were eligible if they were at least 18 years old, had smoked cigarettes at least once in the past 7 days, and were able to provide written informed consent. Index Prenatal participants were eligible to enroll up to 24 weeks gestation. We estimated 20-30 interviews would achieve data saturation. 21 Secondary participants who were (1) referred by an enrolled Index Participant, (2) age 18 years or older, and (3) willing to provide signed, informed consent were considered eligible.
Visual Aids and Moderator Guides
We designed visual aids to illustrate the correlation between maternal cotinine and neonatal NNAL. Visual aids took the form of a brochure ( Figure 1 ) and a larger flip chart illustrating (1) the metabolism of cigarette components nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (a potent tobacco-specific carcinogen) to cotinine and NNAL, respectively, (2) the correlation between maternal cigarette use and maternal urine cotinine levels, and (3) the correlation between maternal cotinine and newborn NNAL levels. All participants received the generalized correlation information. Index Postpartum women were also given their individual cotinine level and their infant's NNAL level collected at or shortly after delivery. Secondary participant questions explored reactions to the generalized correlation information and how they and other friends and family members could provide cessation support to a pregnant family member or friend.
We created three sets of semi-structured moderator guides, one specific to each of the three participant groups. Study investigators and CAB members revised the guides for flow and content. The major topics covered in the moderator guides for Index participants were: utility and acceptability of biomarker feedback intervention content (including visual aids), receiving personal results versus general results on biomarker findings, recruitment and implementation of biomarker feedback intervention for pregnant women, and perceived barriers to participating in a biomarker feedback intervention. We asked Secondary participants to comment on the potential impact of biomarker information on mother's tobacco use and baby's health, providing support for helping pregnant women to quit smoking, and the effect of biomarker information on personal use of tobacco.
Study Procedures
Index Postpartum participants were contacted by phone or mailed a letter. Index Prenatal participants were recruited by study staff during prenatal clinic appointments at the SCF Anchorage Native Primary Care Center located on the ANHC. Both groups of Index participants were interviewed after providing signed informed consent. At interview conclusion, we asked all Index participants whether a family member or friend might be interested in interviewing as a Secondary participant. If so, Index participants were given a prepared letter explaining the study and how to contact the study team. Interviews with eligible Secondary participants who signed informed consent were conducted following the same procedures as the Index interviews including collecting demographic information and tobacco use status, and provision of the generalized correlation information. All participants received a $40 gift card as a thank you for their time.
Interviews were conducted in English, held in a private room in the SCF Primary Care Center or in the participant's home, and led by a trained study moderator. All interviews were audio-recorded and most were attended by a trained study observer. Study moderators and observers received 3 hours of didactic instruction followed by four practice hours of mock interviews and a certified completion interview prior to conducting interviews. Training was conducted in Anchorage by the Mayo Clinic Behavioral Health Research Team.
Each participant was assigned a unique study identifier used to label individual recordings and data. Upon completion of the 45-to 60-minute interview, the moderator and observer summarized responses with each participant, offering an opportunity to clarify or expand their responses.
De-identified interview recordings were transcribed by a private transcription service. Transcriptions were returned to the study team in Anchorage and reviewed for accuracy prior to analysis.
Data Analysis
We used content analysis 22 supplemented by QSR NVivo software, version 10 (Doncaster, Victoria, Australia) to generate response themes. All transcribed interview statements were analyzed. Co-authors CF and CS coded responses independently based on the emergent themes for each topic area (inter-rater agreement of 99.5%). During this joint review, themes were extracted for analysis when there was code endorsement or elaboration by several interviews within or across samples. Saturation, where no new themes emerged, was reached during coding. Discrepancies in coding were resolved through discussion with a third co-author (CP) until consensus was reached. Index participant responses were stratified by whether participants received generalized correlation information (Index Prenatal) or individual cotinine results in addition to the generalized information (Index Postpartum).
Results

Participants
A total of 39 participants were enrolled: 12 Index Postpartum, 16 Index Prenatal, and 11 Secondary participants. Table 1 provides the sample characteristics for the two Index groups. Aside from pregnancy status, the only significant differences between the two Index groups were (1) a lower proportion of Index Postpartum participants (58.3%) reporting spouse/partner tobacco use than Index Prenatal participants (94%, p = .02) and (2) significantly fewer hours of second-hand smoke exposure reported by Index Postpartum participants (mean = 4.2 hours) than by Index Prenatal participants (mean = 10.0 hours, p = .02). 1-(3-pyridyl) -1-butanol) are breakdown products of tobacco and can be measured in urine. Cotinine in a pregnant mother's urine reflects the amount of tobacco she has used. NNAL has been shown to cause cancer. The more tobacco a pregnant woman uses, the more NNAL she and her unborn baby are exposed to. NNAL and cotinine not true to scale. NNAL measured in pg/ mL; cotinine measured in ng/mg-creat.
Secondary participants were predominantly male (64%) with a mean age of 31 years (SD = 4.24); 46% currently smoked cigarettes. All Secondary participants were either a spouse/partner (64%) or immediate relative (36%) of an Index participant.
Index Participant Responses
Utility and Acceptability of Biomarker Feedback Intervention Content Index participants understood the biomarker information presented in brochure and flip chart formats. Participants were asked if they could suggest a better way to present the information; they felt a brochure similar to or the same as the one constructed for this study would be an acceptable way to illustrate and present cotinine and NNAL biomarker information. Overall, participants did not feel AN culture played a significant role when being presented the information, as described by one Index Prenatal participant "I'm not sure. It's not really in my culture to smoke cigarettes and stuff. But there's nothing in my culture that's against it, you know. So I don't think the cultural aspect will really make a difference." A common sentiment expressed was that "Every pregnant woman should know about what it causes and what your unborn baby is getting when you do smoke a cigarette" (Index Prenatal participant), regardless of race or cultural background Supplementary Table 1.
Perceptions and Impact Upon Receiving Personalized or Generalized Results
Index participants were unaware of cotinine and NNAL or how their health or the health of their baby was affected by these chemicals prior to this study. After receiving their personal biomarker results, Index Postpartum women expressed greater concern about the health of their child than their own health. They communicated feelings of guilt over smoking while pregnant and regret they did not know about NNAL. One Index Postpartum participant commented "I feel guilty" and another stated she wished she "could have known this stuff before firsthand." Index Postpartum participants shared that learning their personalized biomarker results inspired them to either quit or cut back smoking now or quit smoking with future pregnancies. One participant commented "It makes me want to quit more…just seeing more results like that." Another stated, "I really want to-need to try to quit. I feel disgusted." However, lower than expected cotinine/NNAL levels did elicit some less motivated responses for cessation, such as "My results were still kind of low, so it doesn't concern me that much. I still like to smoke."
For Index Prenatal women, receiving the generalized correlation information was less helpful in motivating cessation. For example, one woman indicated "I don't really see this as giving me like a real good insight of what it-I think just letting me know what it actually does to your baby while you're smoking cigarettes…this doesn't really help me understand too much about the effects of me smoking while pregnant." These participants thought the generalized information was insufficient, suggesting more evidence regarding fetal exposure to NNAL and cancer risk would be necessary to increase motivation to quit smoking while pregnant.
Recruitment and Implementation of Prenatal Intervention
Both Index study groups agreed posters and pamphlets/flyers were the most effective methods of recruiting pregnant AN women into a biomarker feedback smoking cessation intervention. This proposed intervention would provide information about maternal tobacco use and fetal exposure to tobacco-specific carcinogens. Participants reported receiving the information from a provider (eg, physician, nurse, or Tobacco Cessation Counselor) during a prenatal appointment would be the most acceptable way to deliver the biomarker information.
Additional Intervention Components
The majority of Index participants preferred a face-to-face first encounter with a tobacco cessation counselor. Responses to followup phone call frequency and duration varied. Index participants felt .02 min = minimum; max = maximum; n = number; SD = standard deviation; ST = smokeless tobacco. p < .05 is significant.
counselors should ask women how cessation was going and discuss harmful effects of smoking and second-hand smoke exposure, triggers, and relapse prevention. Index Postpartum women specifically mentioned the information in the biomarker feedback pamphlet as an important discussion item. Index participants indicated a family member or friend should be involved in cessation. Several Index Postpartum women suggested women choose whether to include a support person in the follow-up calls and several Index Prenatal women suggested the support person should be someone who agrees to provide support. Mention was also made of possibly offering a cessation support group.
Barriers to Participating in Biomarker Feedback Intervention
All Index participants received a description of a proposed prenatal biomarker feedback intervention that included the measurement of maternal urine cotinine and receipt of results incorporated with cessation counseling. Prominent perceived barriers to participation included emotions/feelings of fear and guilt upon learning the personalized results as well as time and transportation. Lack of childcare, privacy, phone service, family support in quitting, and denial about the harm tobacco use had on their unborn baby were additional barriers mentioned.
When asked whether cotinine testing should be mandatory, reactions were mixed. For example, one Index Postpartum participant stated, "I think it should be something automatic because I mean it's a matter of concern with the health of the baby and yourself, so in all other aspects besides tobacco they automatically do that. So why would it be different with tobacco?" Meanwhile, an Index Prenatal participant shared "They should (be) warned or asked instead of just throwing it at them."
Secondary Participant Responses
Impact of Biomarker Information on Mother and Baby
After receiving the correlation information, Secondary participants felt strongly that prenatal women should quit smoking because it was bad for the baby: "...my wife shouldn't smoke as long as she is pregnant...She's putting herself and the baby at risk." Another commented, "Well, I think that I had a feeling that it wasn't good in the first place. And this is just good science to back up".
Providing Cessation Support
Secondary participants expressed willingness to help with prenatal smoking cessation. Some indicated they had previously told a partner or friend to quit and/or had actively done things to try to help her quit tobacco: "I don't know. I just told her if she wants to quit, that I would be along right there with her." One participant suggested starting a hobby since the pregnant woman had said she smoked out of boredom.
Participants acknowledged there were many barriers to helping pregnant women quit smoking. Stress was the most common response. Another important barrier was spending a significant amount of time with others who use tobacco. "Well I know her boyfriend also smokes. Mom does too. So that'd probably be some barriers." Another participant stated, "But I know it's going to be hard for her because we're both smokers, so I guess I have to start thinking about quitting then, huh?"
Intervention Components
The majority of Secondary participants stated a family member/ friend should be involved in a cessation intervention. Similar to Index participants, Secondary participant responses varied on frequency and duration of follow-up calls, but offered these items be determined by the woman. Secondary participants suggested counselors inquire how the friend/family member is helping, the effect he/ she is having on quitting, and stress coping mechanisms in addition to discussing health risks to mother and baby.
Effect on Personal Tobacco Use
Some spouses/partners stated learning the biomarker information made them think about or consider cutting back on their smoking or even quitting. When asked about personal tobacco use after learning about cotinine and NNAL, one participant stated, "…I need to do more than cut down. And even though I have cut down, it doesn't seem like it's enough." while another stated, "I've been thinking about that to cut down on it…very hard to do." Others did not feel they needed to quit, but would not use around a pregnant woman. "I'll smoke, but not around her, if it comes to that, you know."
Discussion
Engaging the lay public and/or individuals who represent potential end users in assessing the research findings and providing input on how best to communicate the findings in an accessible format is an important component of research dissemination. 23 Providing feedback to pregnant women on biomarkers of fetal exposure to tobacco could enhance motivation for quitting. 24, 25 Women who continue to smoke during pregnancy believe the risk to their fetus is lower than do women who quit spontaneously. 26, 27 In this context, increasing risk awareness of pregnant tobacco users could be especially effective because fetal health and a desire to be healthy during pregnancy are the most important motivators for quitting. 28, 29, 30 Perceived fetal risk and pregnancy-related tobacco use concerns are important predictors of cessation during pregnancy. However, no prior work has presented information on NNAL as part of a biomarker feedback intervention for pregnant women.
In this qualitative study, we solicited input from AN women and their partners or family members on the acceptability and applicability of population-specific biomarker data about maternal smoking and fetal carcinogen exposure. 11 There was general agreement that the format and information presented in the study brochure were appropriate for and understandable to the target audience. Participants indicated the most acceptable time and person to provide the biomarker information was during prenatal visits with a health care provider or with those involved in tobacco cessation counseling. In addition, participants indicated more widespread dissemination of the information was appropriate.
We observed differences between women who actually received their own cotinine results and those who saw only the generalized findings from Phase I, but did not get their own results. The combination of seeing the association of cotinine and NNAL and having one's own results appeared to have a greater impact on thoughts associated with quitting smoking. However, among women whose cotinine levels are lower than they expected, there is a danger these women may perceive themselves and their unborn child to be at low risk of carcinogen exposure. Additional messaging would need to be developed to address this scenario. One area that may need further exploration is whether pregnancy status or parity may have influenced women's responses to the biomarker feedback. All women who received the individualized results were postpartum, which may have contributed to the difference in responses from women who were pregnant and received only the generalized information. Consistent with our health messaging framework, women for whom the generalized information alone did not motivate behavior change suggested a link needed to be shown between NNAL and the actual effects on the fetus or neonate. A recent metaanalysis reported epigenetic modifications to the fetal DNA as a result of maternal tobacco use. 31 While these epigenetic changes do not prove causation, they do provide a possible mechanism for explaining the health consequences of maternal smoking and provide another biomarker of fetal exposure to maternal smoking. Linking the MAW study correlation findings with the recent epigenetic findings may incentivize cessation among AN women who smoke during pregnancy in situations where personal cotinine testing is not feasible.
The inclusion of family members or friends to support women who want to quit smoking was also supported by participants, reinforcing the suggestions from our CAB to consider the interests of the community in the health and well-being of the newborn. Conversely, the lack of support from family in quitting was seen as a barrier to participation in a smoking cessation intervention. Inclusion of a support person could potentially help with addressing some of the other barriers that were listed, such as transportation, child care, and emotions/feelings of fear and guilt or denial. Feedback from Secondary participants indicated they also were willing to help pregnant women in their quit attempts. Partners also acknowledged it made cessation more difficult for pregnant women to quit if they too were a smoker and, based on the information given, it would be important for them to quit as well.
A major strength of our study is the expansion of the end user group to include family members and friends, acknowledging the importance attached to the community surrounding a pregnant AN woman and her unborn child. These individuals may have a large influence on the success or failure of a tobacco cessation intervention. While the opinions and responses from participants may not represent all AN people, survey data indicate tobacco use varies substantially by Alaska region. We view a pilot study confined to one specific region a study strength and an example of best practice when employing community-based participatory research methods. Repetitious responses were gathered from the interviews in all content areas by the end of enrollment, indicating data saturation was achieved despite the limited sample size. Qualitative data collected from interviews are subject to bias. Multiple actions were taken to ensure accurate interpretation of qualitative responses. Two individuals (moderator and observer) were present for the interview; observers read back notes and interpretations for the participants to validate and add information to, if desired; moderators and observers debriefed after each interview. All interviews were subsequently coded and analyzed separately by two study personnel. Inter-rater agreement for coding was 99.5%.
In summary, information about fetal carcinogen exposure resulting from smoking during pregnancy may be more effective when combined with individual cotinine testing. We are currently evaluating an intervention incorporating our generalized correlation information and individual cotinine testing to determine the effectiveness of this novel biomarker feedback to motivate smoking cessation among pregnant AN women.
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